A Phase 2 interventional study of Apremilast and Placebo in Ulcerative Colitis, sponsored by Amgen. Completed at 99 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-07.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 615 studies in Colitis, Ulcerative with a site in United States — 116 open to participants now, 167 under way, 34 of them phase 3. Colitis, Ulcerative · United States.
Among the 615 studies in Colitis, Ulcerative with a site in United States, this one is the 160th largest by enrollment of the 499 interventional ones that give a count, is one of 33 that started in 2015, is one of 146 in phase 2, and was the 206th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →116 of the 615 studies in Colitis, Ulcerative with a site in United States are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States
Ages 16–80
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
University of Minnesota · Sites in United States
Ages 18+
Muhammad N Aslam, MD · Sites in United States
Ages 18–80
Vanda Pharmaceuticals · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
615 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 87 · Phase 2 173 · Phase 3 132 · Phase 4 33
First in 1995; this study’s year is marked. 33 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 170 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 76 across the 499 interventional studies, 198 across the 113 observational. Of the 407 that completed or were terminated, 192 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
332 of 615 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 7 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
55 of the studies in Colitis, Ulcerative with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
Add all 55 to your calendar (.ics) → With an account.
Among the 615 studies in Colitis, Ulcerative with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the clinical efficacy, safety and tolerability of apremilast (30 mg twice daily [BID] and 40 mg BID), compared with placebo, in participants with active Ulcerative Colitis (UC).
Approximately 165 participants (55 subjects per arm) will be randomized in a 1:1:1 ratio to receive oral apremilast (30 mg BID or 40 mg BID), or identically appearing placebo BID for up to 12 weeks, followed by 40 weeks of blinded treatment with apremilast (30 mg BID or 40 mg BID).
At the end of the Blinded Active-treatment Phase (Week 52), participants who have a Mayo endoscopy score ≤ 1 will have the opportunity to participate in the Extension Phase. Participants enrolled in the Extension Phase will receive apremilast for an additional 52 weeks (Weeks 52 to 104). With the implementation of Amendment 4, participants entering the Extension Phase will receive apremilast 30 mg BID. Subjects currently in the Extension Phase who are receiving apremilast 40 mg BID will be switched to 30 mg BID at the next scheduled visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must satisfy the following criteria to be enrolled in the study:
Exclusion Criteria:
The presence of any of the following will exclude a subject from enrollment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apremilast 30 mg by mouth (PO) twice a day (BID) for 12 weeks After 12 weeks: * Participants who achieve at least a 20% decrease from baseline in the total Mayo score (TMS) will continue to receive apremilast 30 mg BID for an additional 40 weeks. (Wk 52) * Participants who do not achieve at least a 20% decrease from baseline in the TMS will receive apremilast 40 mg BID for an additional 40 weeks (Wk 52) After 52 weeks, participants who are eligible for the Extension Phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)
Drug: Apremilast
Apremilast 40 mg by mouth (PO) twice a day (BID) for 12 weeks After 12 weeks, participants assigned to the 40 mg BID dose of apremilast at baseline will continue to receive apremilast 40 mg BID for an additional 40 weeks (Wk 52) After 52 weeks, participants who are eligible for the extension Phase will continue to receive apremilast 40 mg BID for an additional 52 weeks (Wk 104)
Drug: Apremilast
Identically matching placebo by mouth (PO) twice a day (BID) for 12 weeks. After 12 weeks all participants randomized to placebo at baseline will be re-randomized to receive apremilast 30 mg or 40 mg BID for an additional 40 weeks (Wk 52) After Wk 52, participants who are eligible for the extension phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)
Drug: Apremilast · Drug: Placebo
Also known as: CC-10004; Otezla
Percentage of Participants Who Achieved a Clinical Remission by Total Mayo Score (TMS) at Week 12
Clinical remission was defined as a total Mayo score ≤ 2 points, with no individual subscore exceeding 1 point. The TMS is an instrument designed to measure disease activity of UC. The Mayo score ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease. * Stool Frequency Subscore (SFS) * Rectal Bleeding Subscore (RBS) * Endoscopy Subscore * Physician's Global Assessment (PGA). Two-sided 95% confidence intervals (CI) for the within-group percentages are based on the Wilson score method.
Time frame: Week 12
Percentage of Participants Who Achieved a Clinical Response by Total Mayo Score and the Reduction in the Rectal Bleeding Subscore at Week 12
Clinical response was defined as a decrease from baseline in the TMS of at least 3 points and at least 30%, along with a reduction in the rectal bleeding subscore (RBS) of at least 1 point or an absolute RBS of ≤ 1. The TMS is an instrument designed to measure disease activity of UC. The Mayo score ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease. * Stool Frequency Subscore (SFS) * Rectal Bleeding Subscore * Endoscopy Subscore * Physician's Global Assessment (PGA) Rectal bleeding (subscore 0-3) was defined as: 0 = No blood seen 1. = Streaks of blood with stool less than half the time 2. = Obvious blood with stool 3. = Blood alone passes Two-sided 95% CI for the within-group percentages are based on the Wilson score method.
Time frame: Week 12
Percentage of Participants Who Achieved an Endoscopic Remission at Week 12
An endoscopic remission was defined as a Mayo endoscopic subscore (MES) of 0 at Week 12. The MES subscore findings were defined as: 0 = Normal or inactive disease 1. = Mild Disease (erythema, decreased vascular pattern, mild friability) 2. = Moderate Disease (marked erythema, lack of vascular pattern, friability erosions) 3. = Severe Disease (spontaneous bleeding, ulceration) The endoscopy subscores consisted of findings that were centrally read through proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease. Two-sided 95% CIs for the within-group percentage were based on the Wilson score method.
Time frame: Week 12
Percentage of Participants Who Achieved an Endoscopic Response at Week 12
An endoscopic response is defined as a decrease from baseline of at least 1 point in the MES at Week 12. The Mayo endoscopy subscore findings were defined as: 0 = Normal or inactive disease 1. = Mild Disease (erythema, decreased vascular pattern, mild friability) 2. = Moderate Disease (marked erythema, lack of vascular pattern, friability erosions) 3 = Severe Disease (spontaneous bleeding, ulceration). The endoscopy subscores consisted of findings that were centrally read through proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease. Two-sided 95% CIs for the within-group percentage were based on the Wilson score method.
Time frame: Week 12
Percentage of Participants Who Achieved a Rectal Bleeding Subscore (RBS) of ≤ 1 at Week 12
The RBS was measured as: 0 = No blood seen 1. = Streaks of blood with stool less than half the time 2. = Obvious blood with stool most of the time 3. = Blood alone passes The daily bleeding score represents the most severe bleeding of the day. Two-sided 95% CI for the within-group proportions are based on the Wilson score method.
Time frame: Week 12
Percentage of Participants Who Achieved Clinical Remission in the Modified Mayo Subscore (MMS) at Week 12
Clinical remission was defined as a modified Mayo score of ≤ 2, with no individual subscore \> 1, at Week 12. The MMS was based on a modification of the total Mayo score (TMS) which included the stool frequency, rectal bleeding, and endoscopic subscores of the TMS and excluded the Physician's Global Assessment (PGA) subscore, since this was a global measure that is subjective in nature. The MMS ranges from 0 to 9 points with higher scores indicating greater disease severity. The endoscopy subscores was centrally reviewed. Two-sided confidence intervals for the within-group percentage were based on the Wilson score method.
Time frame: Week 12
Percentage of Participants Who Achieved Clinical Response in the Modified Mayo Subscore (MMS) at Week 12
Clinical response in the MMS was defined as a decrease from baseline in the MMS of at least 2 points and at least 25%, along with a reduction in the RBS of at least 1 point or an absolute RBS ≤ 1. The MMS was based on the stool frequency, rectal bleeding, and endoscopic subscores of the TMS and excluded the PGA subscore. The MMS ranges from 0 to 9 points with higher scores indicating greater disease severity. The RBS was measured as: 0 = No blood seen 1. = Streaks of blood with stool less than half the time 2. = Obvious blood with stool most of the time 3. = Blood alone passes The daily bleeding score represents the most severe bleeding of the day. The endoscopy subscores was centrally reviewed. Two-sided confidence intervals for the within-group percentage were based on the Wilson score method.
Time frame: Week 12
Percentage of Participants Who Achieved Clinical Remission in the Partial Mayo Subscore (PMS) With no Individual Subscore >1 at Week 8
Clinical remission in the partial Mayo subscore was defined as a PMS of 2 points or lower, with no individual subscore \>1. The PMS is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 9 (severe disease) and is a composite of 3 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease). Two-sided 95% CI for the within-group proportions are based on the Wilson score method.
Time frame: Week 8
Percentage of Participants Who Achieved Clinical Response in the Partial Mayo Subscore at Week 8
Clinical response in the PMS was defined as a decrease from baseline in PMS of at least 2 points and at least 25%, with an accompanying decrease in the RBS of at least 1 point or an absolute RBS of 0 or 1. The PMS score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 9 (severe disease) and is a composite of 3 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease). Two-sided 95% CI for the within-group proportions are based on the Wilson score method.
Time frame: Week 8
The Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs) During the Placebo-Controlled Phase
A TEAE was defined as any adverse event (AE) occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain
Time frame: From the first dose of investigational product (IP) and no later than 28 days after the last dose of IP for those who had completed the study or discontinued (D/C) early; maximum duration of exposure to treatment was 12.00 weeks
The Number of Participants Who Discontinued Apremilast Due to Treatment Emergent Adverse Events During the Placebo-Controlled Period
A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain.
Time frame: From the first dose of IP and no later than 28 days after the last dose of IP for those who had completed the study or discontinued early; median duration of exposure to treatment was 12.00 weeks
The Number of Participants Who Experienced TEAEs During the Apremilast (APR) Exposure Period (Active Treatment Phase) Through Week 52
A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain
Time frame: From first dose of IP and no later than 28 days after last dose of IP for those who completed the active treatment phase or D/C early; median duration of exposure = 41.00, 44.15 and 40.00 weeks respectively for 30 mg, 40 mg and 30 mg/40 mg APR arms
The Number of Participants Who Experienced TEAEs During Week 52 to Week 104 (Extension Phase)
A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain
Time frame: From the first dose of IP at Week 52 and no later than 28 days after the last dose of IP for those who completed the study or had discontinued early; median exposure of apremilast for the total apremilast group was 52 weeks.
The study was conducted at 61 sites in Australia (3 sites) and New Zealand (1 site); Bulgaria (6 sites), Czech Republic (2 sites), Hungary (3 sites), Poland (9 sites), Russia (1 site), and Ukraine (10 sites); Canada (2 sites) and United States (13 sites); and France (4 sites), Germany (1 site), Italy (4 sites), and the Netherlands (2 sites).
| Milestone | Placebo | Apremilast 30 mg | Apremilast 40 mg | Placebo/Apremilast 30 mg | Placebo/Apremilast 40 mg | Apremilast 30 mg/Apremilast 40 mg | Apremilast 40 mg/ Apremilast 40 mg | Extension Phase: Apremilast 30 mg | Extension Phase Apremilast 40 mg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 58 | 57 | 55 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 51 | 53 | 52 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 7 | 4 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Apremilast 30 mg | Apremilast 40 mg | Placebo/Apremilast 30 mg | Placebo/Apremilast 40 mg | Apremilast 30 mg/Apremilast 40 mg | Apremilast 40 mg/ Apremilast 40 mg | Extension Phase: Apremilast 30 mg | Extension Phase Apremilast 40 mg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 41 | 42 | 26 | 25 | 12 | 7 | 0 | 0 |
| Completed | 0 | 39 | 32 | 17 | 20 | 7 | 5 | 0 | 0 |
| Not completed | 0 | 2 | 10 | 9 | 5 | 5 | 2 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 4 | 2 | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 4 | 6 | 2 | 3 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Miscellaneous | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Placebo | Apremilast 30 mg | Apremilast 40 mg | Placebo/Apremilast 30 mg | Placebo/Apremilast 40 mg | Apremilast 30 mg/Apremilast 40 mg | Apremilast 40 mg/ Apremilast 40 mg | Extension Phase: Apremilast 30 mg | Extension Phase Apremilast 40 mg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 45 | 54 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 38 | 48 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 6 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Miscellaneous | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Clinical remission was defined as a total Mayo score ≤ 2 points, with no individual subscore exceeding 1 point. The TMS is an instrument designed to measure disease activity of UC. The Mayo score ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease. * Stool Frequency Subscore (SFS) * Rectal Bleeding Subscore (RBS) * Endoscopy Subscore * Physician's Global Assessment (PGA). Two-sided 95% confidence intervals (CI) for the within-group percentages are based on the Wilson score method.
| Percentage of Participants | Placebo | Apremilast 30 mg | Apremilast 40 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved a Clinical Remission by Total Mayo Score (TMS) at Week 12 | 12.1 (6.0 to 22.9) | 31.6 (21.0 to 44.5) | 21.8 (12.9 to 34.4) |
Clinical response was defined as a decrease from baseline in the TMS of at least 3 points and at least 30%, along with a reduction in the rectal bleeding subscore (RBS) of at least 1 point or an absolute RBS of ≤ 1. The TMS is an instrument designed to measure disease activity of UC. The Mayo score ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease. * Stool Frequency Subscore (SFS) * Rectal Bleeding Subscore * Endoscopy Subscore * Physician's Global Assessment (PGA) Rectal bleeding (subscore 0-3) was defined as: 0 = No blood seen 1. = Streaks of blood with stool less than half the time 2. = Obvious blood with stool 3. = Blood alone passes Two-sided 95% CI for the within-group percentages are based on the Wilson score method.
| Percentage of Participants | Placebo | Apremilast 30 mg | Apremilast 40 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved a Clinical Response by Total Mayo Score and the Reduction in the Rectal Bleeding Subscore at Week 12 | 46.6 (34.3 to 59.2) | 61.4 (48.4 to 72.9) | 67.3 (54.1 to 78.2) |
An endoscopic remission was defined as a Mayo endoscopic subscore (MES) of 0 at Week 12. The MES subscore findings were defined as: 0 = Normal or inactive disease 1. = Mild Disease (erythema, decreased vascular pattern, mild friability) 2. = Moderate Disease (marked erythema, lack of vascular pattern, friability erosions) 3. = Severe Disease (spontaneous bleeding, ulceration) The endoscopy subscores consisted of findings that were centrally read through proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease. Two-sided 95% CIs for the within-group percentage were based on the Wilson score method.
| Percentage of Participants | Placebo | Apremilast 30 mg | Apremilast 40 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved an Endoscopic Remission at Week 12 | 3.4 (1.0 to 11.7) | 8.8 (3.8 to 18.9) | 7.3 (2.9 to 17.3) |
An endoscopic response is defined as a decrease from baseline of at least 1 point in the MES at Week 12. The Mayo endoscopy subscore findings were defined as: 0 = Normal or inactive disease 1. = Mild Disease (erythema, decreased vascular pattern, mild friability) 2. = Moderate Disease (marked erythema, lack of vascular pattern, friability erosions) 3 = Severe Disease (spontaneous bleeding, ulceration). The endoscopy subscores consisted of findings that were centrally read through proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease. Two-sided 95% CIs for the within-group percentage were based on the Wilson score method.
| Percentage of Participants | Placebo | Apremilast 30 mg | Apremilast 40 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved an Endoscopic Response at Week 12 | 41.4 (29.6 to 54.2) | 73.7 (61.0 to 83.4) | 47.3 (34.7 to 60.2) |
The RBS was measured as: 0 = No blood seen 1. = Streaks of blood with stool less than half the time 2. = Obvious blood with stool most of the time 3. = Blood alone passes The daily bleeding score represents the most severe bleeding of the day. Two-sided 95% CI for the within-group proportions are based on the Wilson score method.
| Percentage of Participants | Placebo | Apremilast 30 mg | Apremilast 40 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved a Rectal Bleeding Subscore (RBS) of ≤ 1 at Week 12 | 72.4 (59.8 to 82.2) | 84.2 (72.6 to 91.5) | 87.3 (76.0 to 93.7) |
Clinical remission was defined as a modified Mayo score of ≤ 2, with no individual subscore \> 1, at Week 12. The MMS was based on a modification of the total Mayo score (TMS) which included the stool frequency, rectal bleeding, and endoscopic subscores of the TMS and excluded the Physician's Global Assessment (PGA) subscore, since this was a global measure that is subjective in nature. The MMS ranges from 0 to 9 points with higher scores indicating greater disease severity. The endoscopy subscores was centrally reviewed. Two-sided confidence intervals for the within-group percentage were based on the Wilson score method.
| Percentage of Participants | Placebo | Apremilast 30 mg | Apremilast 40 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved Clinical Remission in the Modified Mayo Subscore (MMS) at Week 12 | 19.0 (10.9 to 30.9) | 43.9 (31.8 to 56.7) | 27.3 (17.3 to 40.2) |
Clinical response in the MMS was defined as a decrease from baseline in the MMS of at least 2 points and at least 25%, along with a reduction in the RBS of at least 1 point or an absolute RBS ≤ 1. The MMS was based on the stool frequency, rectal bleeding, and endoscopic subscores of the TMS and excluded the PGA subscore. The MMS ranges from 0 to 9 points with higher scores indicating greater disease severity. The RBS was measured as: 0 = No blood seen 1. = Streaks of blood with stool less than half the time 2. = Obvious blood with stool most of the time 3. = Blood alone passes The daily bleeding score represents the most severe bleeding of the day. The endoscopy subscores was centrally reviewed. Two-sided confidence intervals for the within-group percentage were based on the Wilson score method.
| Percentage of Participants | Placebo | Apremilast 30 mg | Apremilast 40 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved Clinical Response in the Modified Mayo Subscore (MMS) at Week 12 | 46.6 (34.3 to 59.2) | 63.2 (50.2 to 74.5) | 67.3 (54.1 to 78.2) |
Clinical remission in the partial Mayo subscore was defined as a PMS of 2 points or lower, with no individual subscore \>1. The PMS is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 9 (severe disease) and is a composite of 3 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease). Two-sided 95% CI for the within-group proportions are based on the Wilson score method.
| Percentage of Participants | Placebo | Apremilast 30 mg | Apremilast 40 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved Clinical Remission in the Partial Mayo Subscore (PMS) With no Individual Subscore >1 at Week 8 | 32.8 (22.1 to 45.6) | 47.4 (35.0 to 60.1) | 52.7 (39.8 to 65.3) |
Clinical response in the PMS was defined as a decrease from baseline in PMS of at least 2 points and at least 25%, with an accompanying decrease in the RBS of at least 1 point or an absolute RBS of 0 or 1. The PMS score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 9 (severe disease) and is a composite of 3 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease). Two-sided 95% CI for the within-group proportions are based on the Wilson score method.
| Percentage of Participants | Placebo | Apremilast 30 mg | Apremilast 40 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved Clinical Response in the Partial Mayo Subscore at Week 8 | 48.3 (35.9 to 60.8) | 64.9 (51.9 to 76.0) | 81.8 (69.7 to 89.8) |
A TEAE was defined as any adverse event (AE) occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain
| Participants | Placebo | Apremilast 30 mg | Apremilast 40 mg |
|---|---|---|---|
| Any TEAE | 31 | 28 | 36 |
| Any IP-related TEAE | 12 | 13 | 20 |
| Any Severe TEAE | 4 | 0 | 1 |
| Any Serious TEAE | 2 | 0 | 1 |
| Any Serious IP-related TEAE | 0 | 0 | 0 |
| Any TEAE Leading to IP Withdrawal | 5 | 0 | 1 |
| Any TEAE Leading to IP Interruption | 1 | 0 | 0 |
| Any TEAE Leading to Death | 0 | 0 | 0 |
A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain.
| Participants | Placebo | Apremilast 30 mg | Apremilast 40 mg |
|---|---|---|---|
| The Number of Participants Who Discontinued Apremilast Due to Treatment Emergent Adverse Events During the Placebo-Controlled Period | 5 | 0 | 1 |
A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain
| Participants | Apremilast 30 mg | Apremilast 40 mg | Apremilast 30 mg/Apremilast 40 mg |
|---|---|---|---|
| Any TEAE | 60 | 67 | 8 |
| Any Severe TEAE | 5 | 6 | 0 |
| Any Serious TEAE | 6 | 8 | 1 |
| Any TEAE Leading to Drug Withdrawal | 3 | 9 | 1 |
| Any TEAE Leading to Drug Interruption | 1 | 4 | 0 |
| Any TEAE Leading to Death | 0 | 0 | 0 |
A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain
| Participants | Extension Phase: Apremilast 30 mg | Extension Phase: Apremilast 40 mg |
|---|---|---|
| Any TEAE | 16 | 27 |
| Any Severe TEAE | 1 | 0 |
| Any Serious TEAE | 4 | 3 |
| Any Serious IP-related TEAE | 0 | 1 |
| Any TEAE Leading to IP Withdrawal | 2 | 1 |
| Any TEAE Leading to IP Interruption | 1 | 0 |
| Any TEAE Leading to Death | 0 | 0 |
Collected over From the first dose of IP and no later than 28 days after the last dose of IP for those who had completed the study or discontinued early. AEs are reported for the placebo-controlled phase from Week 0 to Week 12 and for the apremilast exposure period from Week 0 to Week 104.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Placebo Controlled Period) | 0/58 (0%) | 2/58 (3.4%) | 20/58 (34.5%) |
| Apremilast 30 mg (Placebo Controlled Period) | 0/57 (0%) | 0/57 (0%) | 26/57 (45.6%) |
| Apremilast 40 mg BID (Placebo Controlled Period) | 0/55 (0%) | 1/55 (1.8%) | 25/55 (45.5%) |
| Apremilast 30 mg (Apremilast Exposure Period) | 0/83 (0%) | 9/83 (10.8%) | 49/83 (59%) |
| Apremilast 40 mg (Apremilast Exposure Period) | 0/80 (0%) | 11/80 (13.8%) | 53/80 (66.3%) |
| Apremilast 30/40 mg (Apremilast Exposure Period) | 0/11 (0%) | 1/11 (9.1%) | 11/11 (100%) |
| Event | Placebo (Placebo Controlled Period) | Apremilast 30 mg (Placebo Controlled Period) | Apremilast 40 mg BID (Placebo Controlled Period) | Apremilast 30 mg (Apremilast Exposure Period) | Apremilast 40 mg (Apremilast Exposure Period) | Apremilast 30/40 mg (Apremilast Exposure Period) |
|---|---|---|---|---|---|---|
| Inguinal herniaGastrointestinal disorders | 0/58 | 0/57 | 0/55 | 0/83 | 0/80 | 1/11 |
| Colitis ulcerativeGastrointestinal disorders | 2/58 | 0/57 | 0/55 | 1/83 | 3/80 | 0/11 |
| Renal colicRenal and urinary disorders | 0/58 | 0/57 | 0/55 | 1/83 | 2/80 | 0/11 |
| PancreatitisGastrointestinal disorders | 0/58 | 0/57 | 1/55 | 0/83 | 1/80 | 0/11 |
| Abdominal herniaGastrointestinal disorders | 0/58 | 0/57 | 0/55 | 0/83 | 1/80 | 0/11 |
| Crohn's diseaseGastrointestinal disorders | 0/58 | 0/57 | 0/55 | 0/83 | 1/80 | 0/11 |
| DiarrhoeaGastrointestinal disorders | 0/58 | 0/57 | 0/55 | 0/83 | 1/80 | 0/11 |
| Epididymitis tuberculousInfections and infestations | 0/58 | 0/57 | 0/55 | 0/83 | 1/80 | 0/11 |
| Rectal abscessInfections and infestations | 0/58 | 0/57 | 0/55 | 0/83 | 1/80 | 0/11 |
| Epididymal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/58 | 0/57 | 0/55 | 0/83 | 1/80 | 0/11 |
| Event | Placebo (Placebo Controlled Period) | Apremilast 30 mg (Placebo Controlled Period) | Apremilast 40 mg BID (Placebo Controlled Period) | Apremilast 30 mg (Apremilast Exposure Period) | Apremilast 40 mg (Apremilast Exposure Period) | Apremilast 30/40 mg (Apremilast Exposure Period) |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 4/58 | 12/57 | 14/55 | 17/83 | 25/80 | 2/11 |
| NauseaGastrointestinal disorders | 5/58 | 3/57 | 6/55 | 8/83 | 9/80 | 3/11 |
| VomitingGastrointestinal disorders | 1/58 | 2/57 | 2/55 | 3/83 | 3/80 | 3/11 |
| AstheniaGeneral disorders | 2/58 | 3/57 | 1/55 | 5/83 | 3/80 | 2/11 |
| DiarrhoeaGastrointestinal disorders | 2/58 | 1/57 | 0/55 | 5/83 | 6/80 | 2/11 |
| PyrexiaGeneral disorders | 2/58 | 1/57 | 1/55 | 1/83 | 2/80 | 2/11 |
| NasopharyngitisInfections and infestations | 1/58 | 4/57 | 2/55 | 7/83 | 8/80 | 2/11 |
| DyspepsiaGastrointestinal disorders | 1/58 | 1/57 | 0/55 | 2/83 | 0/80 | 1/11 |
| Decreased appetiteMetabolism and nutrition disorders | 1/58 | 2/57 | 1/55 | 2/83 | 3/80 | 1/11 |
| Abdominal painGastrointestinal disorders | 1/58 | 3/57 | 0/55 | 4/83 | 3/80 | 1/11 |
The intent to treat (ITT) population consisted of all participants who were randomized and received at least 1 dose of investigational product (IP).
| Age, Continuous(Years) | Placebo | Apremilast 30 mg | Apremilast 40 mg | Total |
|---|---|---|---|---|
| Mean | 42.9 ± 14.04 | 40.1 ± 13.50 | 43.4 ± 14.92 | 42.1 ± 14.15 |
| Sex: Female, Male(Participants) | Placebo | Apremilast 30 mg | Apremilast 40 mg | Total |
|---|---|---|---|---|
| Female | 25 | 18 | 21 | 64 |
| Male | 33 | 39 | 34 | 106 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Apremilast 30 mg | Apremilast 40 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 5 | 8 |
| Not Hispanic or Latino | 55 | 54 | 46 | 155 |
| Unknown or Not Reported | 1 | 2 | 4 | 7 |
| Race/Ethnicity, Customized(Participants) | Placebo | Apremilast 30 mg | Apremilast 40 mg | Total |
|---|---|---|---|---|
| Asian | 0 | 0 | 1 | 1 |
| White | 54 | 52 | 45 | 151 |
| Other | 1 | 1 | 1 | 3 |
| Not Reported or Collected | 3 | 4 | 8 | 15 |
| Duration of Ulcerative Colitis(Years) | Placebo | Apremilast 30 mg | Apremilast 40 mg | Total |
|---|---|---|---|---|
| Mean | 6.85 ± 7.043 | 6.15 ± 5.432 | 8.63 ± 10.278 | 7.19 ± 7.832 |
| Baseline Total Mayo Score (TMS)(units on a scale) | Placebo | Apremilast 30 mg | Apremilast 40 mg | Total |
|---|---|---|---|---|
| Mean | 8.2 ± 1.68 | 8.5 ± 1.62 | 8.1 ± 1.67 | 8.3 ± 1.65 |
| Modified Mayo Score (MMS)(units on a scale) | Placebo | Apremilast 30 mg | Apremilast 40 mg | Total |
|---|---|---|---|---|
| Mean | 6.1 ± 1.51 | 6.4 ± 1.48 | 6.0 ± 1.47 | 6.2 ± 1.49 |
| Partial Mayo Score (PMS)(units on a scale) | Placebo | Apremilast 30 mg | Apremilast 40 mg | Total |
|---|---|---|---|---|
| Mean | 5.6 ± 1.46 | 5.8 ± 1.44 | 5.5 ± 1.57 | 5.6 ± 1.49 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Jan 2015 to primary completion in Sep 2017, 32 months.
Results were first posted in Oct 2018, 1 year 1 month after primary completion. A results delay was requested in Feb 2018.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 32 months is above that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast